Replies to post #3312 on Insmed Inc (INSM)

[rod5247]

Since this is being discussed, perhaps you can address this question I asked in September.

"Posted by: rod5247
In reply to: jellybean who wrote msg# 2971 Date:9/4/2006 6:37:34 PM
Post #of 3312

Looking at Herceptin in comparison with INSM-18, they appear to block the same receptor, (Her2/neu) but INSM-18 inhibits what Herceptin plus BP3 inhibits. "INSM-18, a small molecule tyrosine kinase inhibitor, has demonstrated selective inhibition of the insulin-like growth factor-I receptor (IGF-I) and human epidermal growth factor receptor (Her2/neu)." Since I don't claim to understand all of the scientific data, could this be a valid assumption or could INSM-18 + BP3 be a viable compound?"

FYI Contacted Jody Lomonzo by e-mail yesterday, requesting website update for pipe and IR contact. While no response was received nor expected, was surprised to receive notice my e-mail was read after 6 PM yesterday. Seems our IR Lady is working overtime. She will be a key element for investor confidence and appreciation of market value.